Lowey Dannenberg Notifies Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $250,000 in Losses to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for violations of federal securities laws, alleging misleading statements regarding the safety and efficacy of its Novum LVP medical devices during the specified Class Period [1][2]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased Baxter securities between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter made false statements and failed to disclose critical information about the Novum LVP, including systemic defects leading to malfunctions that posed serious risks to patients [2]. Allegations Against Baxter - Specific allegations include: - Systemic defects in the Novum LVP causing underinfusion, overinfusion, and non-delivery of fluids [2]. - Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2]. - Inadequate remedial measures were taken by Baxter to address these defects, despite ongoing design flaws [2]. - Increased risk of customers removing Novum LVPs from service and halting new sales [2]. - Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading [2]. Impact on Investors - Following the revelation of these issues, Baxter's stock price declined significantly, resulting in substantial losses for investors [3]. - Investors who suffered losses exceeding $250,000 are encouraged to participate in the lawsuit, with a deadline to act by December 15, 2025 [3]. About the Law Firm - Lowey Dannenberg P.C. specializes in representing investors who have suffered financial losses due to corporate fraud and has a history of recovering billions for clients [4].